VetMedMedetomidine vs dexmedetomidine sedation in dogs — POSSIBLE
In dogs, does medetomidine vs dexmedetomidine at equipotent doses give equal sedation with different cardiovascular effects?
Shelf #537 · gate-verified and displayed under the developer's blinded-trial rule
POSSIBLE: At equipotent doses (dexmedetomidine at half the medetomidine dose, milligram for milligram of the active enantiomer), the two drugs made no difference to sedation or analgesia scores in the head-to-head records — the treatment made no difference to sedation, and the differences found were in duration of analgesia and inhalant requirement, not in depth of sedation — both drugs alike changed the breathing pattern, with no difference between them (Pleyers 2020). Kuusela 2000 (PMID: 10747239; 6 Beagles, blinded randomised block study) found the overall level of sedation and cardiorespiratory effects did not differ between medetomidine 40 µg/kg, dexmedetomidine 20 µg/kg and dexmedetomidine 10 µg/kg during the first hour, apparently due to a ceiling effect, although the analgesic effect of dexmedetomidine 20 µg/kg lasted longer than that of the corresponding racemic medetomidine dose, and levomedetomidine alone caused no sedation or analgesia. Kuusela 2001 (PMID: 11453483; 6 Beagles, three dose levels of each drug as premedicants before propofol-isoflurane anaesthesia) found degrees of sedation and analgesia were significantly affected by dose level but not by drug, while combined mean end-tidal isoflurane concentration across dose levels was higher in dogs that received medetomidine than in dogs that received dexmedetomidine, and the middle dose level (medetomidine 4.0 / dexmedetomidine 2.0 µg/kg) gave the most stable cardiovascular effects. Pleyers 2020 (PMID: 32792270; 8 Beagles, randomised blinded crossover) found no difference between dexmedetomidine 10 µg/kg and medetomidine 20 µg/kg in respiratory rate, thoracic impedance change or minute impedance change 10 minutes after intravenous dosing. Design class (a): randomisation and blinding are established by carded records answering the shelf's own comparison and population (Kuusela 2000, a blinded randomised block study; Pleyers 2020, a randomised blinded crossover study). The stamp is POSSIBLE, not higher, because the evidence is three very small Beagle studies (6-8 dogs) from two research groups, sedation and analgesia were scored subjectively, a ceiling effect may have hidden real differences at the high doses tested, and recovery differences were dose-level effects rather than drug effects in the one study that reported recovery. Drafted Nov 10, 2026 (VetMed build, topic #537); all figures from the abstracts fetched and verified at drafting.
Kuusela 2000: medetomidine 40 µg/kg and dexmedetomidine 20 or 10 µg/kg did not differ in overall sedation or cardiorespiratory effects in the first hour in 6 Beagles — dexmedetomidine analgesia lasted longer
Blinded, randomized block clinical trial (record's own wording; publication types: Clinical Trial, Journal Article, Randomized Controlled Trial)
Who: Dogs: 6 Beagle dogs. Each dog received intravenously, in a blinded, randomized block study over six separate sessions: medetomidine 40 µg/kg, dexmedetomidine 20 µg/kg, dexmedetomidine 10 µg/kg, levomedetomidine 20 µg/kg, levomedetomidine 10 µg/kg, and saline placebo. Sedation and analgesia were scored subjectively; heart rate, ECG lead II, direct blood pressure, respiratory rate, arterial blood gases and rectal temperature were monitored, and blood samples were taken for drug analysis.
Result: Peak sedative and analgesic effects were observed at mean (± SD) plasma levels of 18.5 ± 4.7 ng/mL for medetomidine 40, 14.0 ± 4.5 ng/mL for dexmedetomidine 20 and 5.5 ± 1.3 ng/mL for dexmedetomidine 10. The overall level of sedation and cardiorespiratory effects did not differ between medetomidine 40, dexmedetomidine 20 and dexmedetomidine 10 during the first hour, apparently due to a ceiling effect; however, the analgesic effect of dexmedetomidine 20 lasted longer than the effect of the corresponding dose of racemic medetomidine, suggesting greater potency for dexmedetomidine. Levomedetomidine had no effect on cardiovascular parameters and caused no apparent sedation or analgesia. Clearance of levomedetomidine (4.07 ± 0.69 L/h/kg at 20 µg/kg) was more rapid than that of medetomidine 40 (1.26 ± 0.44), dexmedetomidine 20 (1.24 ± 0.48) and dexmedetomidine 10 (0.97 ± 0.33).
Watch out: Six Beagles, subjective sedation and analgesia scoring, and the authors themselves attribute the absence of a difference in the first hour to a ceiling effect at the doses chosen — so this record shows the doses tested were indistinguishable, not that the drugs are identical at every dose. The comparison is intravenous dosing in healthy research dogs.
Kuusela E, Raekallio M, Anttila M, Falck I, Mölsä S, Vainio O. Clinical effects and pharmacokinetics of medetomidine and its enantiomers in dogs. J Vet Pharmacol Ther. 2000;23(1):15-20. PMID: 10747239. Registry ID: none in the record. MeSH: Analgesia/methods, veterinary* · Analgesics, Non-Narcotic/pharmacokinetics*, pharmacology · Animals · Cardiovascular Physiological Phenomena/drug effects · Procedural Sedation/methods, veterinary · Dexmedetomidine/pharmacokinetics*, pharmacology · Dogs · Female · Injections, Intravenous · Male · Medetomidine/pharmacokinetics*, pharmacology
Kuusela 2001: sedation and analgesia depended on dose level, not on drug, across three medetomidine/dexmedetomidine dose levels in 6 Beagles — end-tidal isoflurane was higher after medetomidine
Comparative study (publication types: Comparative Study, Journal Article; the abstract does not state randomisation or blinding)
Who: Dogs: 6 healthy Beagles undergoing propofol-isoflurane anaesthesia, premedicated intravenously with medetomidine or dexmedetomidine at three paired dose levels: 0.4 / 0.2 µg/kg (M0.4/D0.2), 4.0 / 2.0 µg/kg (M4/D2) and 40 / 20 µg/kg (M40/D20). Sedation and analgesia were scored before induction; end-tidal isoflurane concentration, heart rate, arterial blood pressures and gases were measured during anaesthesia.
Result: Degrees of sedation and analgesia were significantly affected by dose level but not by drug. Combined mean end-tidal isoflurane concentration for all dose levels was higher in dogs that received medetomidine, compared with dexmedetomidine. Recovery time was significantly prolonged at the M40/D20 dose level compared with the other dose levels. After induction, blood pressure decreased below reference range and heart rate increased at the M0.4/D0.2 dose level, whereas blood pressure was preserved at M40/D20, although dogs at the higher levels developed profound bradycardia and mild metabolic acidosis during anaesthesia. Treatment at M4/D2 resulted in more stable cardiovascular effects than the other dose levels, and PaCO2 was similar among dose levels. The authors conclude dexmedetomidine is at least as safe and effective as medetomidine as a premedicant in dogs undergoing propofol-isoflurane anaesthesia.
Watch out: Six Beagles and three dose levels spanning a 100-fold range: the sedation comparison is a premedication score before induction, not sedation as the sole endpoint, and the record does not state that treatment order was randomised or assessors blinded. The end-tidal isoflurane difference is reported as a combined mean across dose levels without absolute values in the abstract.
Kuusela E, Raekallio M, Väisänen M, Mykkänen K, Ropponen H, Vainio O. Comparison of medetomidine and dexmedetomidine as premedicants in dogs undergoing propofol-isoflurane anesthesia. Am J Vet Res. 2001;62(7):1073-80. PMID: 11453483. Registry ID: none in the record. MeSH: Adrenergic alpha-Agonists/administration & dosage, pharmacology* · Anesthesia, General/methods, veterinary* · Anesthetics, Inhalation/administration & dosage · Anesthetics, Intravenous/administration & dosage · Animals · Blood Pressure/drug effects · Dexmedetomidine/administration & dosage, pharmacology* · Dogs/physiology* · Dose-Response Relationship, Drug · Female · Heart Rate/drug effects · Hypnotics and Sedatives/administration & dosage, pharmacology* · Isoflurane/administration & dosage · Male · Medetomidine/administration & dosage, pharmacology* · Preanesthetic Medication/veterinary* · Propofol/administration & dosage · Respiration/drug effects · Stereoisomerism
Pleyers 2020: no difference between dexmedetomidine 10 µg/kg and medetomidine 20 µg/kg in respiratory variables in 8 Beagles — both slowed respiratory rate and changed the breathing pattern
Randomized, blinded, crossover study (record's own wording; publication types: Journal Article, Randomized Controlled Trial, Veterinary)
Who: Dogs: 8 healthy adult research Beagles breathing room air, maintained in right lateral recumbency with an electrical impedance tomography belt around the chest. In a randomized, blinded, crossover study with a minimum 10-day washout, each dog received intravenous dexmedetomidine 10 µg/kg or medetomidine 20 µg/kg; respiratory rate and changes in thoracic impedance were recorded for 120 seconds before and exactly 10 minutes after dosing.
Result: Overall, respiratory rate decreased from 26 (22-29) movements/minute before dosing to 13 (10-21) at 10 minutes (p = 0.003) and thoracic impedance change increased from 1.133 (0.856-1.599) to 1.650 (1.273-2.813) arbitrary units (p = 0.007), but minute impedance change did not change (30.375 [23.411-32.445] before vs 30.581 [22.487-35.091] arbitrary units/minute at 10 minutes). There was no difference between dexmedetomidine and medetomidine. Most dogs developed a peculiar breathing pattern of clusters of breaths followed by short periods of apnoea; the authors interpret both drugs as reducing respiratory rate and increasing tidal volume without impacting minute volume.
Watch out: This card answers the cardiovascular/respiratory-effects half of the question, not sedation depth: no sedation score is reported, the observation window is a single 10-minute time point, and 8 research Beagles breathing room air are not clinical sedation patients.
Pleyers T, Levionnois O, Siegenthaler J, Spadavecchia C, Raillard M. Investigation of selected respiratory effects of (dex)medetomidine in healthy Beagles. Vet Anaesth Analg. 2020;47(5):667-671. PMID: 32792270. Registry ID: none in the record. MeSH: Animals · Cross-Over Studies · Dexmedetomidine/pharmacology* · Dogs* · Female · Hypnotics and Sedatives/pharmacology* · Male · Medetomidine/pharmacology* · Respiratory Physiological Phenomena/drug effects*
Synthesis: at equipotent (2:1) doses the two drugs sedate equally in the records found; dexmedetomidine analgesia lasted longer in one study and isoflurane requirement was lower in another — POSSIBLE
Synthesis
Who: Synthesis of the three cards above: Kuusela 2000 (6 Beagles, blinded randomised block, intravenous), Kuusela 2001 (6 Beagles, three paired dose levels as premedicants) and Pleyers 2020 (8 Beagles, randomised blinded crossover, respiratory outcomes).
Result: (1) Sedation/analgesia: no drug difference at equipotent doses in either Kuusela study — scores were driven by dose level, not drug (2001), and overall sedation did not differ between medetomidine 40 and dexmedetomidine 20 or 10 µg/kg in the first hour (2000). (2) Duration: dexmedetomidine 20 µg/kg analgesia lasted longer than medetomidine 40 µg/kg (Kuusela 2000). (3) Cardiovascular/respiratory: cardiorespiratory effects did not differ overall in Kuusela 2000; both drugs produced dose-dependent bradycardia at high doses and the middle dose level was most stable (Kuusela 2001); respiratory variables did not differ between the drugs (Pleyers 2020). (4) Inhalant: combined mean end-tidal isoflurane was higher after medetomidine than after dexmedetomidine (Kuusela 2001). (5) Design class (a): randomisation and blinding are established by Kuusela 2000 and Pleyers 2020, carded records answering this shelf's own comparison in this shelf's own population.
Watch out: One-home check at drafting: PMIDs 10747239, 11453483 and 32792270 do not appear in any other pack on disk. Records deliberately not carded as claim-carriers: Kuusela 2001 on levomedetomidine (PMID: 11327474) tests the inactive enantiomer against dexmedetomidine, not medetomidine against dexmedetomidine as clinical products; Salla 2017 (PMID: 29076369) varies MK-467/glycopyrrolate added to medetomidine, with no dexmedetomidine arm; the medetomidine-vatinoxan versus dexmedetomidine record (PMID: 42880347) compares a combination product, not medetomidine alone. Boundary: dexmedetomidine versus acepromazine premedication is Shelf #317 — a different comparison, desk-checked and not used here. All carded evidence is intravenous dosing in small numbers of healthy Beagles; intramuscular clinical sedation in patients is not directly tested by any carded record.
Synthesis of Kuusela E et al. PMID: 10747239; Kuusela E et al. PMID: 11453483; Pleyers T et al. PMID: 32792270. Registry IDs as on the individual cards.
Back to the library index · VetMed home
VetMed is an educational resource, not veterinary advice.